3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Recurrence
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Stomach Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Appendiceal Neoplasms
1
Interventions
temsirolimus
2
Sunitinib
2
Sorafenib
2
Axitinib
2
sonidegib
1
niraparib
1
lenvatinib
1
gadolinium ethoxybenzyl DTPA
1
donafenib
1
Transurethral Resection of Prostate
1
Therapeutics
1
Phlebotomy
1
Palliative Care
1
Mitomycin
1
Methylation
1
Maintenance
1
Interviews as Topic
1
Hyperthermic Intraperitoneal Chemotherapy
1
HhAntag691
1
Hepatectomy
1
Fatty Acids, Omega-6
1
Endoscopy
1
Cetuximab
1
Breath Tests
1
Blood Specimen Collection
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Carcinoma
×
Mitomycin
×
Clear all
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled